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In 1999, the National Diabetes Prevention and Control
Program at the Centers for Disease Control and
Prevention and its 59 Diabetes Prevention and Control
Programs adopted five Healthy People 2010 objectives.
These objectives aim to improve the rates of preventive
care services among people with diabetes and include
annual foot examinations, hemoglobin A1c tests, and
annual dilated eye examinations. This paper examines
progress toward meeting these three objectives.
Methods
Questions from the diabetes module of the Behavioral
Risk Factor Surveillance System (BRFSS) were used to
evaluate changes in age-adjusted rates for annual foot
examinations, hemoglobin A1c tests, and annual dilated
eye examinations of 44 jurisdictions between 2000 and
2003. Questions from the diabetes module were also used
to compare percentage rates of 47 jurisdictions in 2003
with Healthy People 2010 percentage targets.
Results
From 2000 to 2003, for the 44 jurisdictions, the aggre-
gate, age-adjusted rate of annual foot examinations
increased from 63.7% to 69.3% (P < .001); the rate of self-
reported hemoglobin A1c tests increased from 68.3% to
69.5% (P = .35); and the rate of annual dilated eye exami-
nations decreased from 67.7% to 65.2% (P = .05). In 2003,
20 of 47 jurisdictions met the Healthy People 2010 target
for foot or eye examinations, and all 47 jurisdictions met
the target for hemoglobin A1c tests. An inverse association
was found between baseline rates in 2000 and the magni-
tude of change from 2000 to 2003 for all three national dia-
betes objectives.
Conclusion
The National Diabetes Prevention and Control Program
should consider adopting additional Healthy People 2010
objectives. Baseline rates should be considered in 1)
selecting objectives, 2) setting percentage targets, and 3)
evaluating current or future objectives. Program-related
information should be linked with traditional data sources
such as BRFSS so that we can understand the role of envi-
ronmental factors and evaluate progress of jurisdictions
toward national diabetes objectives.
Introduction
Diabetes and its associated burden are continuously
evolving (1). More than 18 million adults in the United
States have diabetes (2). People with diabetes are at
increased risk of developing complications such as blind-
ness, lower extremity amputations, end-stage renal disease,
and cardiovascular disease (2). Although recommended pre-
ventive care services can prevent or delay the development
of these serious health complications (3-6), the proportion of
adults with diabetes who report receiving preventive care
services is less than what we hope for (7-8).
Increasing the rates of preventive care services among
people with diabetes is an objective of Healthy People 2010
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(HP2010), a program established by the U.S. Department
of Health and Human Services (9). In 1999, the National
Diabetes Prevention and Control Program (NDPCP),
established by the Centers for Disease Control and
Prevention (CDC), adopted three of the 17 HP2010 dia-
betes objectives and two of the HP2010 immunization
objectives. The five objectives adopted include percentage
targets for annual hemoglobin A1c (HbA1c) tests, annual
dilated eye examinations, annual foot examinations, and
influenza and pneumococcal vaccinations (Table 1).
Hereafter, we refer to these objectives as national diabetes
objectives. This report focuses on the following three
national diabetes objectives and their percentage targets
for the U.S. population with diabetes: 1) 50% receive an
HbA1c measurement at least twice each year, 2) 75%
receive an annual dilated eye examination, and 3) 75%
receive an annual foot examination. Implementation
strategies used to help achieve these objectives are
described elsewhere (10).
The NDPCP supports a Diabetes Prevention and Control
Program (DPCP) in each of the 50 U.S. states, 8 territories,
and the District of Columbia (10), or jurisdictions. The 59
DPCPs strive to reduce the preventable burden of diabetes
and its associated complications in their jurisdictions by
building collaborations and working closely with their
partners. These partners include managed care organiza-
tions, policy makers, and the American Diabetes
Association and its local affiliates (10). When the NDPCP
adopted the five national diabetes objectives, it asked the
DPCPs to increase target percentage rates for each objec-
tive within their jurisdiction. The NDPCP itself did not set
these targets because it recognized that DPCPs vary in
capacity and funding.
Methods
To evaluate progress toward national diabetes objec-
tives, we analyzed data on diabetes preventive care servic-
es from the Behavioral Risk Factor Surveillance System
(BRFSS). The BRFSS is a state-based, randomized tele-
phone survey of the noninstitutionalized U.S. population
aged 18 years and older. BRFSS surveys are conducted in
each of 50 U.S. states, the District of Columbia, and three
U.S. territories (the U.S. Virgin Islands, Puerto Rico, and
Guam). The optional diabetes module contains 12 dia-
betes-specific questions; these questions are asked of peo-
ple who identify themselves as having diabetes (11). People
with diabetes were defined as those who answered yes to
the core BRFSS question, “Has a doctor ever told you that
you have diabetes?” Women who were told that they had
diabetes only during pregnancy were excluded from the
analysis. Individuals who refused to answer or had miss-
ing or unknown values for any variable were also excluded
from the analysis. In addition, data from Guam and the
U.S. Virgin Islands were excluded from the analysis.
We analyzed responses to three preventive care prac-
tice questions from the diabetes module: 1) “When was
the last time you had an eye examination in which the
pupils were dilated?” 2) “About how many times in the
last year has a health professional checked your feet for
any sores or irritations?” and 3) “A test for hemoglobin ‘A
one C’ measures the average level of blood sugar over the
past 3 months. About how many times in the past 12
months has a doctor, nurse, or other health professional
checked you for hemoglobin ‘A one C’?” People with dia-
betes who reported receipt of at least one dilated eye
examination, one foot examination, or two or more HbA1c
tests in the past year were defined as having received
these preventive care services.
Forty-four jurisdictions used the diabetes module in both
2000 and 2003 (10); 47 used the diabetes module in 2003.
First, we calculated the percentage of people with diabetes
who reported receipt of the three selected preventive care
services for the 44 jurisdictions. Second, we compared the
percentages for 47 jurisdictions that used the module in
2003 with HP2010 percentage targets. All rates were age-
adjusted to the 2000 U.S. standard population. T-tests
were used to determine whether differences between 2000
and 2003 were statistically significant. No correction was
made for multiple testing of the three outcomes. We used
simple linear regression to assess the association between
baseline rates in 2000 and the magnitude of change
between 2000 and 2003 rates. Analyses were conducted
using SAS 9.1 (SAS Institute Inc, Cary, NC) and SUDAAN
9.0 (RTI International, Research Triangle Park, NC).
Results
From 2000 to 2003, the aggregate age-adjusted rate for
foot examinations increased from 63.7% to 69.3% (Table 2);
the rate for HbA1c tests increased from 68.3% to 69.5%
(Table 3), and the rate for dilated eye examinations
decreased from 67.7% to 65.2%(Table 4). Only the increase
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Age-adjusted rates for foot examinations increased in 26
(59%) jurisdictions (Table 2), rates for HbA1c tests
increased in 33 (75%) jurisdictions (Table 3), and rates for
dilated eye examinations increased in 15 (34%) jurisdic-
tions (Table 4). Compared with interquartile ranges for all
three tests in 2000, interquartile ranges are smaller in
2003 (Figure 1). However, overall ranges are large for both
2000 and 2003. In 2003, rates for foot examinations ranged
from 47.0% to 82.4%, rates for HbA1c tests ranged from
53.6% to 85.5%, and rates for eye examinations ranged
from 45.8% to 81.6% (Figure 1). These ranges are similar
to ranges for 2000. The ranges for 2000 were 42.1% to
85.1% for foot examinations, 40.5% to 80.5% for HbA1c
tests, and 51.0% to 89.0% for eye examinations (Figure 1).
Compared with HP2010 targets, the 2003 data from 47
jurisdictions showed that 11 (23%) jurisdictions met the
75% target for foot examination (Table 2), nine (19%) met
the 75% target for dilated eye examination (Table 4), and
all jurisdictions met the 50% target of at least two HbA1c
tests per year (Table 3).The following five states were at or
above the HP2010 targets for all three objectives:
Delaware, Hawaii, Massachusetts, Minnesota, and New
Hampshire (Tables 2-4).
An inverse association was found between the baseline
rate in 2000 and the magnitude of change between 2000
and 2003. Jurisdictions that had relatively low baseline
rates in 2000 were more likely to show an increase in 2003
or to maintain their baseline rates. Jurisdictions with rel-
atively high baseline rates in 2000 were more likely to
show a decrease in 2003. For every unit increase in the
baseline percentage rate in 2000, the predicted 2003 rate
decreased as follows: for foot examination by 0.66% (Figure
2; F value = 52.4; P < .001); for HbA1c tests by 0.69%
(Figure 3; F value = 34.7; P < .001), and for eye examina-
tion by 0.46% (Figure 4; F value = 9.7; P = .003).
Discussion
Factors affecting the rate of receipt of preventive care
services are numerous and include an individual’s knowl-
edge about the importance of obtaining the recommended
tests and examinations, access to diabetes care, availabili-
ty of health insurance, extent of health insurance coverage
for diabetes care services, and the adherence of health care
providers to recommended diabetes care guidelines (10).
Our findings show an inverse association between the
baseline rates of the three selected preventive care servic-
es and the magnitude of change in rates from 2000 to 2003.
This negative association may result from the statistical
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Figure 1. Percentage rates for annual foot examination, two or more annual
hemoglobin A1c (HbA1c) tests, and annual dilated eye examination for 47
jurisdictions, Behavioral Risk Factor Surveillance System, 2000 and 2003.
Overall range, interquartile range, and median are indicated.
Figure 2. Regression of change in 2003 rates for annual foot examinations
on 2000 baseline rates for 44 jurisdictions, Behavioral Risk Factor
Surveillance System data.VOLUME 3: NO. 1
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phenomenon known as regression toward the mean. In
regression toward the mean, rates that are initially high or
initially low eventually move toward the average because
the initial performance occurred by chance (e.g., as a result
of measurement error) or was caused by a factor unrelated
to the intervention (12). A ceiling effect could also explain
the negative association. With a ceiling effect, the initial
impact of an intervention on rates may be large, but once
rates reach a certain threshold, the intervention does not
yield the same rate increases; rates may then reach a
plateau or even decrease. The negative association
between baseline rates and magnitude in change should be
studied further.
The inverse association between baseline rates in 2000
and the predicted rates for 2003 confirms that it would not
be appropriate for the NDPCP to evaluate the performance
of a jurisdiction exclusively on the basis of rate increases or
decreases. Moreover, 20 (42%) of 47 jurisdictions have
already reached the HP2010 target of 75% for foot or eye
examinations, and an additional 27 (57%) jurisdictions
have rates between 70% and 75%. These jurisdictions are
likely to experience a ceiling effect. Additionally, other
revisions to the HP2010 targets are being considered. The
proposed targets are as follows: 91% of people with diag-
nosed diabetes receive an annual foot examination, 76% of
people with diagnosed diabetes receive an annual dilated
eye examination, and 65% of people with diagnosed dia-
betes receive at least two HbA1c tests annually (13). In
2003, the highest rate for foot examinations was 82.5%;
jurisdictions are likely to struggle to reach the 91% target. 
Regardless of whether new HP2010 revisions are adopt-
ed, the NDPCP should consider setting multilevel objec-
tives instead of expecting all jurisdictions to show continu-
ous rate increases. For example, jurisdictions below or at
certain rates could aim to increase rates while jurisdictions
with high rates (e.g., above 75%) could strive to maintain
these rates and adopt new objectives. The idea of setting
multilevel objectives is supported by evidence of the dis-
parity in rates for national diabetes objectives among juris-
dictions (Figure 1).
In addition to considering multilevel targets, the NDPCP
should consider moving from the process-focused objective
of increasing the percentage of people with diabetes who
receive at least two HbA1c tests to an outcome-focused
objective such as reducing the percentage of people with
poor glycemic control assessed through measuring HbA1c
values. Currently, all 47 jurisdictions analyzed in this
study have achieved the HP2010 objective of 50% for at
least two HbA1c tests, and 32 (68%) jurisdictions  have
achieved a rate of more than 70% (Table 3). Strong evi-
dence supports a significant correlation between glycemic
control and microvascular and cardiovascular disease risk
and mortality rates (5). For example, in the U.K.
Prospective Diabetes Study, each 1% reduction in HbA1c
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Figure 3. Regression of change in 2003 rates for two or more annual
hemoglobin A1c tests on 2000 baseline rates for 44 jurisdictions,
Behavioral Risk Factor Surveillance System data.
Figure 4. Regression of change in 2003 rates for annual dilated eye exami-
nations on 2000 baseline rates for 44 jurisdictions, Behavioral Risk Factor
Surveillance System data.levels was associated with a 37% reduction in risk for
diabetic peripheral neuropathy, diabetic retinopathy,
and diabetic nephropathy, conditions responsible for
lower-extremity amputation, blindness, and end-stage
renal disease (5).
State-level data on HbA1c values are available through
the Health Plan Employer Data and Information Set
(HEDIS). Currently, few jurisdictions use this data source;
possible barriers to use include lack of access to the data,
cost, not having an epidemiologist on staff, and complexity
of data analysis (14).
Findings from this study have important implications for
the NDPCP and its partners, especially as the CDC moves
to align its priorities toward health promotion and preven-
tion of disease, injury, and disability outcomes through
improving quality of health by stages of life (15). The
NDPCP and its partners will have opportunities to revise
and add new national diabetes objectives to reduce the pre-
ventable burden of diabetes. Jurisdictions that are close to
meeting or have already met the HP2010 objectives will be
good candidates to pioneer new objectives. New national
diabetes objectives could be selected from existing HP2010
diabetes objectives, or entirely new objectives could be
developed and adopted.
Program-related information should be linked with tra-
ditional data sources such as the BRFSS so that we can
understand the role of environmental factors as we evalu-
ate the progress of jurisdictions toward national diabetes
objectives. For program evaluation, it is imperative to
understand why some jurisdictions perform better than
others. It is especially important to examine jurisdictions
that had high baseline rates in 2000 and showed rate
increases in 2003. A range of environmental factors are
likely to influence jurisdiction performance. These factors
include budget, resources, leadership, partnerships, public
health infrastructure, policies, and specific interventions.
We need to understand how the adoption and sustainabil-
ity of clinical and community-based interventions are effec-
tive in increasing preventive care services. To evaluate the
impact of the effort of a jurisdiction on national diabetes
objectives, we must identify and possibly modify existing
data sources that contain program-related information.
For several years, the NDPCP has been building capaci-
ty to capture program-related information in its own elec-
tronic management information system (MIS). The MIS is
a Web-based system designed to facilitate the collection and
sharing of program-related information among state-based
diabetes prevention and control programs and the NDPCP.
The NDPCP is refining the MIS to link it with traditional
data sources such as the BRFSS. When it is completed, the
MIS will enable NDPCP to measure the association
between the effort of each jurisdiction and its impact on
rates of preventive care services. Enhancing the MIS will
allow the NDPCP and jurisdictions to gain a better under-
standing of the influence of environmental factors.
Our findings are subject to several limitations. The
BRFSS collects data through telephone surveys that
exclude institutionalized people (e.g., nursing home resi-
dents) and people without telephones. The exclusion of
these populations, particularly people without telephones,
could result in overestimation of people receiving the three
preventive care services, assuming that such people are
likely to be less educated, poor, and therefore less likely to
receive preventive care (16,17). The BRFSS data are also
self-reported and subject to recall bias.
Additionally, the BRFSS data reflect statewide
changes; they do not reflect changes that are taking
place in special populations. Additional data sources
such as Medicare and Medicaid records are needed for a
more robust analysis of progress in achieving national
diabetes objectives for such populations. Finally, com-
paring single-year data (2000 with 2003) could be a pos-
sible limitation, but if we had pooled years (i.e., 2000 and
2001 compared with 2002 and 2003), we would not have
had a sufficient time lag for comparison.
Conclusion
The progress of jurisdictions toward achieving national
diabetes objectives cannot be evaluated based on simple
increases or decreases in their rates of preventive care
services. Baseline rates should be considered in evaluating
their progress toward achieving national diabetes objec-
tives. There is a need for developing and adopting new
objectives, especially for the jurisdictions that have already
met or are close to reaching HP2010 objectives. Gaining
better understanding of the environmental factors that
affect each jurisdiction — such as budget, policy, and
health care coverage — is critical for appreciating and
evaluating progress. To evaluate the impact of the effort of
a jurisdiction on rates of national diabetes objectives, we
VOLUME 3: NO. 1
JANUARY 2006
www.cdc.gov/pcd/issues/2006/jan/05_0122.htm • Centers for Disease Control and Prevention 5
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions. Use of trade names is for identification only
and does not imply endorsement by any of the groups named above.VOLUME 3: NO. 1
JANUARY 2006
must identify and modify existing data sources (e.g., the
MIS) that contain program-related information. Linking
this system with traditional data sets such as the BRFSS
could help identify and quantify the underlying factors
vital to progress toward national diabetes objectives.
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Tables
Table 1. Selected Healthy People 2010 Objectives Adopted by the National Diabetes Prevention and Control Program
(NDPCP) as National Diabetes Objectives, 1999
5-12. Persons with diabetes have a glycosylated hemoglobin (HbA1c)  50% 47 (100) By 2004, demonstrate an increase in 
measurement at least twice per year. percentage of persons with diabetes who 
receive the recommended HbA1c measurements.
5-13. Persons with diabetes have an annual dilated eye examination. 75% 9 (19) By 2004, demonstrate an increase in percentage of 
persons with diabetes who receive the recommended 
dilated eye examination.
5-13. Persons with diabetes have an annual foot examination. 75% 11 (23) By 2004, demonstrate an increase in percentage of 
persons with diabetes who receive the recommended 
foot examination.
14-29: a-b. To increase the proportion of noninstitutionalized adults  90% NAb By 2004, demonstrate an increase in percentage of
aged 65 or older who are vaccinated annually against influenza and   persons with diabetes who receive the recommended 
ever against pneumococcal disease.  flu and pneumococcal vaccination.
14-29: c-d. To increase the proportion of noninstitutionalized adults  60% NAb By 2004, demonstrate an increase in percentage of 
aged 18-64 who are vaccinated annually against influenza and ever  persons with diabetes who receive the recommended
against pneumococcal disease. flu and pneumococcal vaccination.
aBased on data from the Behavioral Risk Factor Surveillance System, 2003.
bNA indicates not applicable; these objectives were not measured as part of this study.
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Selected Healthy People 2010 Diabetes Objectives
No. (%) of 
Jurisdictions 
at or Above 
Targeta National Diabetes
Objective Target (n = 47) ObjectivesVOLUME 3: NO. 1
JANUARY 2006
Table 2. Age-Adjusted Data on Prevalence of Annual Foot Examination Among Adults Aged 18 and Older With Diabetes,
Behavioral Risk Factor Surveillance System, United Statesa
All jurisdictions 63.7 (61.6-65.8) 69.3 (67.8-70.8) 5.7 4.31 <.001
Alabama 68.5 (60.8-76.2) 69.9 (63.2-76.7) 1.4 0.28 .78
Alaska 85.1 (76.0-94.1) 66.8 (54.8-78.8) –18.2 2.37 .01
Arizona 69.6 (52.2.-87.0) 67.2 (56.8-77.5) –2.4 0.24 .81
Arkansas 48.1 (39.1-57.2) 57.8 (51.3-64.2) 9.6 1.70 .08
California 62.2 (52.3-72.0) 62.4 (55.3-69.5) 0.2 0.04 .96
Colorado 52.1 (38.3-65.9) 70.9 (63.5-78.2) 18.8 2.35 .01
Connecticut 70.1 (62.2-78.0) 70.5 (63.8-77.1) 0.4 0.07 .94
Delaware NAf 77.7 (71.4-84.0) —- —- —-
District of Columbia 71.1 (60.3-81.9) NAf —- —- —-
Florida 60.2 (52.8-67.5) 72.2 (65.6-78.8) 12.0 2.39 .01
Georgia 65.8 (58.7-72.9) 75.7 (71.1-80.2) 9.9 2.30 .02
Hawaii 75.2 (67.9-82.4) 81.4 (75.5-87.3) 6.3 1.32 .18
Idaho 56.0 (48.4-63.6) 67.9 (61.4-74.4) 11.9 2.34 .01
Illinois NAf NAf —- —- —-
Indiana 58.3 (49.3-67.3) 70.2 (65.1-75.3) 11.9 2.26 .02
Iowa 62.0 (52.4-71.6) 71.9 (65.6-78.2) 9.9 1.68 .09
Kansas 62.9 (55.3-70.4) 69.5 (63.0-76.0) 6.6 1.31 .19
Kentucky 63.8 (57.1-70.5) 63.5 (57.7-69.3) –0.3 0.07 .94
Louisiana 70.3 (64.2-76.5) 71.8 (66.3-77.4) 1.5 0.36 .72
Maine 84.0 (77.2-90.7) 73.0 (64.4-81.6) –10.9 1.96 .04
Maryland NAf 71.2 (63.6-78.8) —- —- —-
Massachusetts 69.2 (63.3-75.0) 79.1 (73.7-84.5) 9.9 1.94 .01
Michigan 56.9 (48.8-64.9) NAf —- —- —-
Minnesota 82.0 (74.0-89.9) 82.4 (76.3-88.5) 0.4 0.08 .93
Mississippi 70.1 (62.1-78.1) NAf —- —- —-
Missouri 63.1 (54.1-72.1) 76.5 (69.6-83.3) 13.3 2.31 .02
8 Centers for Disease Control and Prevention • www.cdc.gov/pcd/issues/2006/jan/05_0122.htm
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions. Use of trade names is for identification only
and does not imply endorsement by any of the groups named above.
2000 2003
% (95% CIb) (95%  CIb) Change
Jurisdiction Nc = 47  Nd = 47  Ne = 44 t1 P value
(Continued on next page) aData from Guam and U.S. Virgin Islands not included.
bCI indicates confidence interval.
cNumber of jurisdictions with 2000 data.
dNumber of jurisdictions with 2003 data.
eNumber of jurisdictions with data for 2000 and 2003.
fNA indicates data not available.Montana 80.3 (72.0-88.5) 74.8 (67.4-82.2) –5.4 0.96 .33
Nebraska 73.9 (65.1-82.6) 71.5 (65.2-77.8) –2.4 0.44 .66
Nevada 80.6 (69.1-92.1) 64.4 (53.9-75.0) –16.1 2.03 .04
New Hampshire 73.7 (62.1-85.3) 79.0 (73.2-84.7) 5.3 0.80 .42
New Jersey 57.1 (48.8-65.4) 69.6 (65.1-74.1) 12.5 2.59 <.001
New Mexico 70.6 (62.9-78.3) 78.4 (73.3-83.4) 7.8 1.66 .09
New York NAf 79.8 (74.4-85.1) —- —- —-
North Carolina 70.7 (62.8-78.6) 77.2 (72.6-81.7) 6.4 1.38 .16
North Dakota 81.1 (71.7-90.6) 72.9 (64.4-81.4) –8.3 1.28 .20
Ohio 65.0 (54.6-75.4) 63.6 (55.6-71.7) –1.4 0.21 .83
Oklahoma 63.5 (54.9-72.1) 64.0 (59.2-68.8) 0.5 0.10 .91
Oregon NAf NAf —- —- —-
Pennsylvania 71.5 (63.6-79.4) 78.1 (72.1-84.1) 6.6 1.29 .19
Rhode Island 74.2 (66.4-81.9) 65.4 (57.4-73.4) –8.7 1.54 .12
South Carolina 72.4 (65.4-79.4) 70.1 (65.1-75.1) –2.3 0.52 .60
South Dakota 75.7 (69.4-79.4) 73.0 (67.4-78.7) –2.6 0.61 .54
Tennessee 60.3 (51.6-69.0) 65.8 (58.4-73.2) 5.6 0.95 .33
Texas 58.5 (52.0-65.0) 61.6 (56.2-66.9) 3.0 0.71 .48
Utah 66.1 (54.7-77.6) 73.3 (65.5-81.2) 7.2 1.02 .30
Vermont 68.8 (59.7-77.8 ) 72.1 (65.3-78.9) 3.4 0.58 .55
Virginia 51.9 (37.7-66.1) 73.0 (66.9-79.0) 21.0 2.67 .007
Washington 72.9 (65.9-80.2) 71.5 (68.2-74.9) –1.4 0.34 .73
West Virginia 74.0 (67.1-80.8) 64.0 (57.9-70.2) –9.9 2.11 .03
Wisconsin 64.8 (55.8-73.8) 71.1 (63.1-79.0) 6.2 1.02 .30
Wyoming 61.5 (50.5-72.4) 70.8 (64.3-77.4) 9.4 1.45 .14
Puerto Rico 42.1 (34.8-49.4) 47.0 (41.0-53.1) 4.9 1.01 .31
aData from Guam and U.S. Virgin Islands not included.
bCI indicates confidence interval.
cNumber of jurisdictions with 2000 data.
dNumber of jurisdictions with 2003 data.
eNumber of jurisdictions with data for 2000 and 2003.
fNA indicates data not available.
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Table 2. (continued) Age-Adjusted Data on Prevalence of Annual Foot Examination Among Adults Aged 18 and Older With
Diabetes, Behavioral Risk Factor Surveillance System, United Statesa
2000 2003
% (95% CIb) (95%  CIb) Change
Jurisdiction Nc = 47  Nd = 47  Ne = 44 t1 P valueVOLUME 3: NO. 1
JANUARY 2006
Table 3. Age-Adjusted Data on Prevalence of Two or More Annual Hemoglobin A1c Tests Among Adults Aged 18 and Older
With Diabetes, Behavioral Risk Factor Surveillance System, United Statesa
All jurisdictions 68.3  (66.2-70.4) 69.5 (67.8-71.2) 1.2 0.91 .35
Alabama 71.7 (63.2-80.1) 73.7 (67.1-80.2) 2.0 0.40 .71
Alaska 68.5 (53.1-83.8) 70.9 (59.8-82.1) 2.5 0.26 .79
Arizona 40.5 (24.7-56.3) 63.9 (52.1-75.8) 23.4 2.30 .02
Arkansas 61.0 (51.1-71.0) 67.4 (61.0-73.8) 6.4 1.05 .29
California 78.7 (71.0-86.4) 53.6 (45.8-61.4) –25.1 4.49 <.001
Colorado 57.2 (43.2-71.2) 67.8 (60.1-75.5) 10.6 1.30 .19
Connecticut 74.4 (66.6-82.2) 76.1 (69.5-82.7) 1.7 0.32 .74
Delaware NAf 70.3 (62.7-77.9) —- —- —-
District of Columbia 64.9 (52.6-77.3) NAf —- —- —-
Florida 70.2 (63.0-77.3) 67.3 (59.3-75.4) –2.8 0.51 .60
Georgia 58.6 (50.2-66.9) 70.4 (64.7-76.1) 11.8 2.30 .02
Hawaii 80.5 (73.9-87.0) 85.5 (80.4-90.7) 5.1 1.2 .23
Idaho 57.3 (49.4-65.3) 57.3 (49.7-65.0) 0.0 —- .99
Illinois NAf NAf —- —- —-
Indiana 73.2 (65.3-81.1) 71.3 (65.9-76.8) –1.9 0.38 .70
Iowa 60.9 (50.5-71.2) 76.1 (70.1-82.0) 15.2 2.51 .01
Kansas 59.4 (51.3-67.5) 74.8 (68.5-81.1) 15.4 2.90 .003
Kentucky 72.1 (65.2-79.0) 70.4 (65.1-75.7) –1.7 0.38 .70
Louisiana 57.4 (65.2-64.7) 62.9 (56.6-69.1) 5.4 1.11 .27
Maine 73.3 (63.3-83.3) 78.2 (56.6-86.5) 4.9 0.73 .46
Maryland NAf 72.6 (64.8-80.5) —- —- —-
Massachusetts 71.7 (65.7-77.7) 78.3 (72.7-83.9) 6.6 1.56 .11
Michigan 72.6 (64.8-80.5) NAf —- —- —-
Minnesota 70.9 (60.8-81.0) 77.7 (71.1-84.3) 6.9 1.12 .26
Mississippi 62.6 (53.0-72.2) NAf —- —- —-
Missouri 65.9 (56.7-75.1) 76.9 (70.3-83.4) 10.9 1.90 .05
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2000 2003
% (95% CIb)  % (95% CIb) Change
Jurisdiction Nc = 47  Nd = 47  Ne = 44 t1 P value
(Continued on next page) aData from Guam and U.S. Virgin Islands not included.
bCI indicates confidence interval.
cNumber of jurisdictions with 2000 data.
dNumber of jurisdictions with 2003 data.
eNumber of jurisdictions with data for 2000 and 2003.
fNA indicates data not available.Montana 59.9 (47.4-72.4) 69.8 (61.6-78.0) 9.9 1.31 .19
Nebraska 67.4 (56.2-78.5) 72.6 (66.3-79.0) 5.3 0.81 .42
Nevada 60.7 (41.0-80.3) 64.2 (52.8-75.6) 3.5 0.31 .76
New Hampshire 78.7 (68.2-89.1) 77.8 (71.7-83.8) –0.9 0.15 .88
New Jersey 74.1 (66.1-82.1) 74.5 (70.2-78.9) 0.4 0.10 .92
New Mexico 60.4 (50.6-70.2) 67.4 (60.5-74.3) 7.0 1.14 .25
New York NAf 81.3 (75.8-86.9) —- —- —-
North Carolina 62.3 (53.7-70.8) 73.9 (68.6-79.2) 11.6 2.27 .02
North Dakota 72.8 (59.5-86.1) 63.0 (53.5-72.4) –9.8 1.17 .24
Ohio 63.2 (52.3-74.1) 74.1 (66.3-81.8) 10.9 1.59 .11
Oklahoma 61.1 (51.8-70.3) 65.7 (60.6-70.7) 4.6 0.85 .39
Oregon NAf NAf —- —- —-
Pennsylvania 69.0 (60.1-78.0) 79.0 (72.6-85.5) 10.0 1.77 .07
Rhode Island 69.6 (61.0-78.3) 70.3 (61.8-78.8) 0.7 0.11 .91
South Carolina 65.9 (57.7-74.1) 72.4 (67.7-77.2) 6.5 1.35 .18
South Dakota 71.3 (64.2-78.4) 80.1 (74.9-85.4) 8.8 1.96 .04
Tennessee 60.7 (52.0-69.3) 73.1 (66.7-79.6) 12.5 2.26 .02
Texas 64.8 (58.1-71.5) 64.4 (58.8-69.9) –0.4 0.08 .93
Utah 57.6 (44.8-70.3) 73.4 (66.0-80.7) 15.8 2.11 .03
Vermont 65.0 (55.6-74.4) 72.6 (65.5-79.7) 7.6 1.26 .21
Virginia 74.0 (62.7-85.3) 70.2 (63.7-76.6) –3.8 0.58 .56
Washington 64.8 (56.6-73.1) 72.0 (68.5-75.5) 7.2 1.57 .11
West Virginia 68.1 (60.1-76.1) 81.3 (75.8-86.7) 13.1 2.66 .008
Wisconsin 63.2 (53.9-72.6) 76.9 (69.4-84.4) 13.7 2.23 .02
Wyoming 61.6 (50.6-72.6) 66.2 (58.9-73.6) 4.7 0.69 .49
Puerto Rico 58.5 (50.0-67.1) 67.7 (61.6-73.8) 9.1 1.71 .08
aData from Guam and U.S. Virgin Islands not included.
bCI indicates confidence interval.
cNumber of jurisdictions with 2000 data.
dNumber of jurisdictions with 2003 data.
eNumber of jurisdictions with data for 2000 and 2003.
fNA indicates data not available.
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Table 3. (continued) Age-Adjusted Data on Prevalence of Two or More Annual Hemoglobin A1c Tests Among Adults Aged 18
and Older With Diabetes, Behavioral Risk Factor Surveillance System, United Statesa
2000 2003
% (95% CIb) (95%  CIb) Change
Jurisdiction Nc = 47  Nd = 47  Ne = 44 t1 P valueVOLUME 3: NO. 1
JANUARY 2006
Table 4. Age-Adjusted Data on Prevalence of Dilated Eye Examination Among Adults Aged 18 and Older With Diabetes,
Behavioral Risk Factor Surveillance System, United Statesa
All jurisdictions 67.7 (65.6-69.8) 65.2 (63.6-66.8) –2.6 1.92 .05
Alabama 67.3 (59.1,75.5) 61.9 (55.0-68.8) –5.5 1.00 .31
Alaska 82.6 (71.5-93.7) 63.3 (50.6-76.1) –19.3 2.24 .02
Arizona 73.9 (57.9-89.9) 64.8 (53.7-75.8) –9.2 0.93 .35
Arkansas 62.2 (53.5-71.0) 57.6 (51.2-64.1) –4.6 0.83 .40
California 64.4 (54.8-74.1) 54.6 (47.2-62.0) –9.8 1.59 .11
Colorado 65.8 (53.0-78.7) 63.2 (55.2-71.2) –2.6 0.34 .73
Connecticut 76.8 (69.7-83.9) 77.3 (71.1-83.5) 0.5 0.10 .91
Delaware NAf 75.0 (68.0-81.9) —- —- —-
District of Columbia 78.0 (68.1-87.9) NAf —- —- —-
Florida 66.7 (59.7-73.7) 72.3 (65.6-79.0) 5.6 1.12 .26
Georgia 61.6 (54.4-68.8) 62.4 (56.8-68.1) 0.8 0.18 .85
Hawaii 79.2 (72.2-86.2) 81.2 (74.3-88.0) 2.0 0.39 .69
Idaho 51.0 (43.4-58.6) 59.4 (52.3-66.5) 8.4 1.58 .11
Illinois NAf NAf —- —- —-
Indiana 62.8 (53.8-71.7) 56.3 (50.7-62.0) –6.5 1.20 .23
Iowa 69.8 (61.4-78.2) 72.5 (66.1-78.9) 2.7 0.50 .61
Kansas 62.3 (54.5-70.2) 72.2 (65.8-78.6) 9.9 1.91 .05
Kentucky 73.7 (67.7-79.7) 63.2 (57.5-68.8) –10.5 2.51 .01
Louisiana 63.6 (57.2-69.9) 66.3 (60.6-71.9) 2.7 1.91 .53
Maine 62.0 (50.9-73.2) 66.4 (57.5-75.2) 4.3 2.50 .55
Maryland NAf 78.4 (72.4-84.5) —- —- —-
Massachusetts 73.3 (67.6-79.0) 81.6 (76.6-86.6) 8.3 0.60 .03
Michigan 77.0 (70.2-83.7) NAf —- —- —-
Minnesota 73.6 (63.2-84.0) 81.5 (75.1-87.9) 8.0 2.16 .20
Mississippi 54.8 (45.8-63.9) NAf —- —- —-
Missouri 65.3 (56.4-74.1) 66.1 (58.6-73.7) 0.9 0.15 .88
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2000 2003
% (95% CIb)  % (95% CIb) Change
Jurisdiction Nc = 47  Nd = 47  Ne = 44 t1 P value
(Continued on next page) aData from Guam and U.S. Virgin Islands not included. 
bCI indicates confidence interval. 
cNumber of jurisdictions with 2000 data. 
dNumber of jurisdictions with 2003 data. 
eNumber of jurisdictions with data for 2000 and 2003. 
fNA indicates data not available.Montana 76.2 (66.2-86.1) 73.8 (66.0-81.7) –2.4 0.36 .71
Nebraska 81.9 (72.9-90.9) 72.4 (66.1-78.8) –9.4 1.68 .09
Nevada 74.1 (61.2-87.0) 45.8 (35.6-55.9) –28.4 3.38 <.000
New Hampshire 89.0 (82.1-95.8) 78.4 (72.8-84.0) –10.5 2.33 .01
New Jersey 75.8 (69.0-82.6) 69.7 (65.4-74.0) –6.1 1.49 .13
New Mexico 69.0 (61.0-76.9) 70.2 (64.1-76.3) 1.2 0.24 .81
New York NAf 73.5 (67.7-79.2) —- —- —-
North Carolina 68.4 (60.7-76.0) 72.8 (68.0-77.7) 4.5 0.97 .33
North Dakota 67.9 (54.5-81.3) 63.7 (54.4-73.1) –4.2 0.50 .61
Ohio 70.5 (60.3-80.7) 63.0 (55.1-70.9) –7.5 1.14 .25
Oklahoma 64.9 (56.3-73.5) 62.4 (57.6-67.1) –2.6 0.51 .60
Oregon NAf NAf —- —- —-
Pennsylvania 76.2 (68.5-84.0) 67.1 (59.7-74.5) –9.1 1.67 .09
Rhode Island 77.5 (70.4-84.6) 69.8 (62.6-77.1) –7.7 1.48 .13
South Carolina 66.1 (58.4-73.8) 63.7 (58.6-68.9) –2.3 0.50 .61
South Dakota 76.2 (69.4-83.0) 79.4 (74.4-84.5) 3.3 0.75 .45
Tennessee 70.3 (62.3-78.4) 80.9 (75.5-86.2) 10.6 2.14 .03
Texas 61.2 (54.9-67.6) 57.6 (52.2-62.9) –3.7 0.87 .38
Utah 75.1 (65.5-84.6) 58.9 (50.0-67.7) –16.2 2.44 .01
Vermont 76.6 (68.7-84.4) 64.1 (56.9-71.4) –12.5 2.28 .02
Virginia 59.9 (45.0-74.8) 63.0 (56.6-69.5) 3.2 0.38 .70
Washington 66.6 (58.7-74.6) 67.8 (64.2-71.3) 1.1 0.25 .80
West Virginia 61.9 (54.0-69.7) 61.8 (55.4-68.1) –0.1 0.02 .98
Wisconsin 75.0 (67.0-82.9) 67.9 (59.6-76.1) –7.1 1.21 .22
Wyoming 62.8 (52.0-73.6) 61.6 (54.2-69.0) –1.2 0.18 .86
Puerto Rico 59.7 (52.5-66.9) 50.6 (44.5-56.7) –9.1 1.90 .05
aData from Guam and U.S. Virgin Islands not included. 
bCI indicates confidence interval. 
cNumber of jurisdictions with 2000 data. 
dNumber of jurisdictions with 2003 data. 
eNumber of jurisdictions with data for 2000 and 2003. 
fNA indicates data not available.
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Table 4. (continued) Age-Adjusted Data on Prevalence of Dilated Eye Examination Among Adults Aged 18 and Older With
Diabetes, Behavioral Risk Factor Surveillance System, United Statesa
2000 2003
% (95% CIb) (95%  CIb) Change
Jurisdiction Nc = 47  Nd = 47  Ne = 44 t1 P value